ConductScience.org, home

Paper33403255

Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.

Chapa R and 8 others. ACS Omega, 2020. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide. Papers, record 33403255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33403255

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.
PubMed
Journal
ACS Omega
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
1.84
iCite
Revised in PubMed
2021-01-11
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chapa RRevathi
2Li CYCindy Yanfei
3Basit AAbdul
4Thakur AAarzoo
5Ladumor MKMayur K
6Sharma SSheena
7Singh SSaranjit
8Selen AArzu
9Prasad BBhagwat

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References70

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122183505Diuretic use in renal disease.Nat Rev Nephrol2011https://conductscience.org/library/papers/22183505PubMed
27654491Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.Br J Clin Pharmacol1995https://conductscience.org/library/papers/7654491PubMed
326927285A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.Pharmacogenomics J2017https://conductscience.org/library/papers/26927285PubMed
415039294Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.Drug Metab Dispos2004https://conductscience.org/library/papers/15039294PubMed
522591The pharmacologic effects of furosemide therapy in the low-birth-weight infant.J Pediatr1978https://conductscience.org/library/papers/22591PubMed
610845101The Na-K-Cl cotransporter of secretory epithelia.Annu Rev Physiol2000https://conductscience.org/library/papers/10845101PubMed
716639716Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.J Pharm Sci2006https://conductscience.org/library/papers/16639716PubMed
82185908Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).Clin Pharmacokinet1990https://conductscience.org/library/papers/2185908PubMed
921051535Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.Drug Metab Dispos2011https://conductscience.org/library/papers/21051535PubMed
107313302Pharmacokinetics of drugs in blood II. Unusual distribution and storage effect of furosemide.Res Commun Chem Pathol Pharmacol1981https://conductscience.org/library/papers/7313302PubMed
114614441Pharmacokinetics and pharmacodynamics of Lasix.Scott Med J1974https://conductscience.org/library/papers/4614441PubMed
1229318651Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide.Br J Clin Pharmacol2018https://conductscience.org/library/papers/29318651PubMed
1319960529Biowaiver monographs for immediate release solid oral dosage forms: furosemide.J Pharm Sci2010https://conductscience.org/library/papers/19960529PubMed
1426945326Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure.Pediatr Crit Care Med2016https://conductscience.org/library/papers/26945326PubMed
159017769Variable furosemide absorption and poor predictability of response in elderly patients.Pharmacotherapy1997https://conductscience.org/library/papers/9017769PubMed
1628322941Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.J Pharm Sci2017https://conductscience.org/library/papers/28322941PubMed
1731176778Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics.Life Sci2019https://conductscience.org/library/papers/31176778PubMed
1818272304Application and limitation of inhibitors in drug-transporter interactions studies.Int J Pharm2008https://conductscience.org/library/papers/18272304PubMed
1919035874Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.Cardiovasc Ther2008https://conductscience.org/library/papers/19035874PubMed
2027621205Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics.Drug Metab Dispos2016https://conductscience.org/library/papers/27621205PubMed

See all 70 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
42662739Transporter Interactions of Methoxyflavones and Their In Vivo Pharmacokinetic Implications.ACS Omega2026https://conductscience.org/library/papers/42662739PubMed
42328646Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.Front Pharmacol2026https://conductscience.org/library/papers/42328646PubMed
42198245Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments.Pharmaceutics2026https://conductscience.org/library/papers/42198245PubMed
41729123Lack of Modulation of In Vivo Activity of Organic Anion Transporters 1 and 3 in Pregnancy Using Furosemide as a Probe.J Clin Pharmacol2026https://conductscience.org/library/papers/41729123PubMed
41304732Predicting Pharmacokinetics of Drugs in Patients with Heart Failure and Optimizing Their Dosing Strategies Using a Physiologically Based Pharmacokinetic Model.Pharmaceutics2025https://conductscience.org/library/papers/41304732PubMed
40425954
Risk Assessment for Biopharmaceutics Classification System Class IV Molecule Containing Immediate Release Products: Use of In-Silico Prediction Tools and Physiologically Based Pharmacokinetic Modeling.
AAPS J2025https://conductscience.org/library/papers/40425954PubMed
38675460Solid Self-Nanoemulsifying Drug Delivery Systems of Furosemide: In Vivo Proof of Concept for Enhanced Predictable Therapeutic Response.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38675460PubMed
38431761A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer.Prostate Cancer Prostatic Dis2025https://conductscience.org/library/papers/38431761PubMed
38156758Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling.CPT Pharmacometrics Syst Pharmacol2024https://conductscience.org/library/papers/38156758PubMed
37896187The Impact of Inflammation on the In Vivo Activity of the Renal Transporters OAT1/3 in Pregnant Women Diagnosed with Acute Pyelonephritis.Pharmaceutics2023https://conductscience.org/library/papers/37896187PubMed
36839862Interplay of Breast Cancer Resistance Protein (Bcrp/Abcg2), Sex, and Fed State in Oral Pharmacokinetic Variability of Furosemide in Rats.Pharmaceutics2023https://conductscience.org/library/papers/36839862PubMed
36769175Kidney Drug Transporters in Pharmacotherapy.Int J Mol Sci2023https://conductscience.org/library/papers/36769175PubMed
35288804Consideration of Fractional Distribution Parameter fd in the Chen and Gross Method for Tissue-to-Plasma Partition Coefficients: Comparison of Several Methods.Pharm Res2022https://conductscience.org/library/papers/35288804PubMed
35149540
Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Drug Metab Dispos2022https://conductscience.org/library/papers/35149540PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33403255

GET https://conductscience.org/api/papers/v1/33403255/references?page=2